Related Experiment Video
Updated: May 4, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells
Carolyn A Goard1, Michelle Chan-Seng-Yue, Peter J Mullen
1Ontario Cancer Institute and Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.
Abstract:
Statins, routinely used to treat hypercholesterolemia, selectively induce apoptosis in some tumor cells by inhibiting the mevalonate pathway. Recent clinical studies suggest that a subset of breast tumors is particularly susceptible to lipophilic statins, such as fluvastatin. To quickly advance statins as effective anticancer agents for breast cancer treatment, it is critical to identify the molecular features defining this sensitive subset. We have therefore characterized fluvastatin sensitivity by MTT assay in a panel of 19 breast cell lines that reflect the molecular diversity of breast cancer, and have evaluated the association of sensitivity with several clinicopathological and molecular features. A wide range of fluvastatin sensitivity was observed across breast tumor cell lines, with fluvastatin triggering cell death in a subset of sensitive cell lines. Fluvastatin sensitivity was associated with an estrogen receptor alpha (ERα)-negative, basal-like tumor subtype, features that can be scored with routine and/or strong preclinical diagnostics. To ascertain additional candidate sensitivity-associated molecular features, we mined publicly available gene expression datasets, identifying genes encoding regulators of mevalonate production, non-sterol lipid homeostasis, and global cellular metabolism, including the oncogene MYC. Further exploration of this data allowed us to generate a 10-gene mRNA abundance signature predictive of fluvastatin sensitivity, which showed preliminary validation in an independent set of breast tumor cell lines. Here, we have therefore identified several candidate predictors of sensitivity to fluvastatin treatment in breast cancer, which warrant further preclinical and clinical evaluation.
Insights
Statins like fluvastatin show promise in treating breast cancer by inducing tumor cell death. Sensitivity is linked to estrogen receptor alpha-negative, basal-like tumors, with a 10-gene signature predicting response.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Statins inhibit the mevalonate pathway, inducing apoptosis in some cancer cells.
- Lipophilic statins, like fluvastatin, show particular efficacy in a subset of breast tumors.
- Identifying molecular features of statin-sensitive breast tumors is crucial for therapeutic advancement.
Purpose of the Study:
- To characterize fluvastatin sensitivity in diverse breast cancer cell lines.
- To identify molecular and clinicopathological features associated with fluvastatin sensitivity.
- To develop a predictive signature for fluvastatin response in breast cancer.
Main Methods:
- MTT assays were used to assess fluvastatin sensitivity across 19 breast cancer cell lines.
- Clinicopathological and molecular features were correlated with observed sensitivity.
- Public gene expression datasets were mined to identify candidate sensitivity-associated genes, including MYC.
- A 10-gene mRNA abundance signature was developed and preliminarily validated.
Main Results:
- A wide range of fluvastatin sensitivity was observed, with a subset of cell lines showing significant cell death.
- Sensitivity was strongly associated with estrogen receptor alpha (ERα)-negative, basal-like breast tumor subtypes.
- Genes involved in mevalonate production, lipid homeostasis, and cellular metabolism, including MYC, were identified as potential correlates.
- A 10-gene signature demonstrated preliminary predictive value for fluvastatin sensitivity.
Conclusions:
- Fluvastatin exhibits selective efficacy against certain breast cancer subtypes, particularly ERα-negative, basal-like tumors.
- Estrogen receptor status and basal-like subtype are potential biomarkers for fluvastatin sensitivity.
- A 10-gene mRNA signature may predict response to fluvastatin, warranting further investigation.
- These findings support further preclinical and clinical evaluation of statins as breast cancer therapeutics.
